BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33822848)

  • 1. Comprehensive characterization of alternative splicing in renal cell carcinoma.
    Zhang Y; Wu X; Li J; Sun K; Li H; Yan L; Duan C; Liu H; Chen K; Ye Z; Liu M; Xu H
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33822848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
    Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma.
    Li Z; Chen Y; Hu S; Zhang J; Wu J; Ren W; Shao N; Ying X
    Oncotarget; 2016 Dec; 7(50):82671-82685. PubMed ID: 27705920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
    Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
    BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
    Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
    Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
    Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
    Duan Y; Zhang D
    J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Characterization of Renal Cell Carcinoma: A Potential Three-MicroRNA Prognostic Signature.
    Lokeshwar SD; Talukder A; Yates TJ; Hennig MJP; Garcia-Roig M; Lahorewala SS; Mullani NN; Klaassen Z; Kava BR; Manoharan M; Soloway MS; Lokeshwar VB
    Cancer Epidemiol Biomarkers Prev; 2018 Apr; 27(4):464-472. PubMed ID: 29440068
    [No Abstract]   [Full Text] [Related]  

  • 10. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma.
    Shiina H; Igawa M; Breault J; Ribeiro-Filho L; Pookot D; Urakami S; Terashima M; Deguchi M; Yamanaka M; Shirai M; Kaneuchi M; Kane CJ; Dahiya R
    Clin Cancer Res; 2003 Jun; 9(6):2121-32. PubMed ID: 12796377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatic identification of renal cell carcinoma microenvironment-associated biomarkers with therapeutic and prognostic value.
    Zeng Q; Zhang W; Li X; Lai J; Li Z
    Life Sci; 2020 Feb; 243():117273. PubMed ID: 31926244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of genes and pathways involved in kidney renal clear cell carcinoma.
    Yang W; Yoshigoe K; Qin X; Liu JS; Yang JY; Niemierko A; Deng Y; Liu Y; Dunker A; Chen Z; Wang L; Xu D; Arabnia HR; Tong W; Yang M
    BMC Bioinformatics; 2014; 15 Suppl 17(Suppl 17):S2. PubMed ID: 25559354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell analysis reveals metastatic cell heterogeneity in clear cell renal cell carcinoma.
    Liu K; Gao R; Wu H; Wang Z; Han G
    J Cell Mol Med; 2021 May; 25(9):4260-4274. PubMed ID: 33759378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 17-Gene Signature Predicted Prognosis in Renal Cell Carcinoma.
    Li F; Hu W; Zhang W; Li G; Guo Y
    Dis Markers; 2020; 2020():8352809. PubMed ID: 32184905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering the Role of ERBB3 Isoforms in Renal Cell Carcinoma: A Comprehensive Genomic and Transcriptomic Analysis.
    Kim M; Lee HH; Won SD; Jang Y; Kim BG; Cho NH; Choi YD; Chung JS; Han HH
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38276060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes.
    Malouf GG; Su X; Yao H; Gao J; Xiong L; He Q; Compérat E; Couturier J; Molinié V; Escudier B; Camparo P; Doss DJ; Thompson EJ; Khayat D; Wood CG; Yu W; Teh BT; Weinstein J; Tannir NM
    Clin Cancer Res; 2014 Aug; 20(15):4129-40. PubMed ID: 24899691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy.
    Zaman S; Hajiran A; Coba GA; Robinson T; Madanayake TW; Segarra DT; Chobrutskiy BI; Boyle TA; Zhou JM; Kim Y; Mulé JJ; Teer JK; Manley BJ
    Eur Urol Focus; 2021 Mar; 7(2):373-380. PubMed ID: 31901438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
    Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
    Front Immunol; 2021; 12():657951. PubMed ID: 34531849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.